Fina Biosolutions is pleased to announce that the Serum Institute of India Private Limited (SIIPL), has completed a Phase 3 study for Pneumosil® a 10-valent pneumococcal conjugate vaccine, in which the Serum Institute indicates all primary and secondary objectives were met. Pneumosil covers over 70% of invasive pneumococcal-disease causing serotypes and employs conjugation chemistry licensed from Fina Biosolutions under a 2007 technology agreement.
{iframe}https://www.businesswire.com/news/home/20190326005027/en/Fina-Biosolutions%E2%80%99-Licensee-Successfully-Completes-Phase-3{/iframe}